Browse the corpus

Acute leukemia, which includes acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), results from the malignant transformation of hematopoietic progenitor cells. This process leads to the accumulation of immature blasts in the bone marrow, disrupting normal hematopoiesis.[1] Please see StatPearls' companion resource, "Acute Myeloid Leukemia," for more information. This transformation is driven by a combination of genetic factors, such as inherited syndromes (eg, trisomy 21 and neurofibromatosis type 1) and acquired mutations (eg, FLT3, NPM1, and CEBPA), and environmental factors, including ionizing radiation, benzene exposure, and viral infections such as human T-lymphotropic virus type 1 (HTLV-1). Please see StatPearls' companion resource, "Leukemia," for more information. The epidemiology of acute leukemia shows distinct patterns for ALL and AML, primarily influenced by age distribution. ALL is the most common malignancy in children, whereas AML is the predominant form of acute leukemia in adults.[2] The complexity of the disease is further highlighted by its diverse classifications, including B-cell ALL (B-ALL), T-cell ALL (T-ALL), and various AML subtypes defined by specific genetic mutations.[3] Laboratory evaluation is crucial for diagnosing acute leukemia, which involves a comprehensive array of tests. Complete blood count (CBC) and peripheral blood smear (PBS) tests assess the quantity and morphology of blood cells.[4] Bone marrow aspiration and biopsy (BMA/BMB) provide detailed information on bone marrow cellularity, morphology, the extent of reticulin fibrosis, iron storage, and blast percentage. Please see StatPearls' companion resource, "Laboratory Evaluation of Bone Marrow," for more information. Flow cytometry is used to identify cell surface markers, aiding in classifying leukemia subtypes.[5]

Laboratory evaluation is crucial for diagnosing acute leukemia, which involves a comprehensive array of tests. Complete blood count (CBC) and peripheral blood smear (PBS) tests assess the quantity and morphology of blood cells.[4] Bone marrow aspiration and biopsy (BMA/BMB) provide detailed information on bone marrow cellularity, morphology, the extent of reticulin fibrosis, iron storage, and blast percentage. Please see StatPearls' companion resource, "Laboratory Evaluation of Bone Marrow," for more information. Flow cytometry is used to identify cell surface markers, aiding in classifying leukemia subtypes.[5] Cytogenetic analysis, including karyotyping and fluorescence in situ hybridization (FISH), detects chromosomal abnormalities. Please see StatPearls' companion resource, "Genetics, Cytogenetic Testing And Conventional Karyotype," for more information. Molecular studies, such as polymerase chain reaction (PCR) and next-generation sequencing (NGS), identify specific gene mutations and translocations. Monitoring minimal residual disease (MRD) is crucial for timely intervention and treatment adjustments to prevent relapse.[6] Effective collaboration among healthcare professionals ensures accurate result interpretation and optimal treatment strategies, ultimately improving patient outcomes and quality of life.

Acute leukemia originates from the malignant transformation of hematopoietic stem cells (HSCs) or early progenitor cells. This process results in the accumulation of immature blasts in the bone marrow, disrupting normal hematopoiesis and impairing the production of healthy blood cells. The molecular mechanisms driving this transformation are diverse and complex, involving a combination of genetic and epigenetic alterations that deregulate key cellular processes. Common Pathophysiological Features of Acute Leukemia Both ALL and AML share several common pathophysiological features, as mentioned below. Suppression of normal hematopoiesis: The proliferation of leukemic blasts within the bone marrow displaces normal hematopoietic cells, resulting in reduced production of mature blood cells and the associated clinical manifestations.[22] Infiltration of extramedullary sites: Leukemic blasts may invade organs and tissues beyond the bone marrow, leading to organ dysfunction and additional clinical symptoms.[23] Genetic instability: Acute leukemia cells often exhibit genetic instability, acquiring additional mutations that drive disease progression and contribute to resistance to treatment.[24] Immune dysregulation: The immune system has a complex role in acute leukemia, exhibiting both anti-leukemic and pro-leukemic effects that influence disease development and progression.[25] Acute Lymphoblastic Leukemia ALL arises from lymphoid progenitor cells, primarily B-cell progenitors and, less commonly, T-cell progenitors. The accumulation of malignant blasts in the bone marrow disrupts the production of normal red blood cells, white blood cells, and platelets, resulting in anemia, increased infection risk, and bleeding tendencies. These blasts may also infiltrate organs such as the lymph nodes, spleen, liver, and central nervous system (CNS), leading to organomegaly and neurological symptoms.[3] The pathophysiology of ALL involves diverse genetic alterations, such as chromosomal translocations, aneuploidy, and mutations in genes regulating B-cell development and signaling pathways. These genetic aberrations lead to the uncontrolled proliferation and impaired differentiation of lymphoblasts, leading to their accumulation and the characteristic clinical manifestations of ALL.[26]

The pathophysiology of ALL involves diverse genetic alterations, such as chromosomal translocations, aneuploidy, and mutations in genes regulating B-cell development and signaling pathways. These genetic aberrations lead to the uncontrolled proliferation and impaired differentiation of lymphoblasts, leading to their accumulation and the characteristic clinical manifestations of ALL.[26] Chromosomal alterations in acute lymphoblastic leukemia: Chromosomal alterations are critical in the pathogenesis of ALL, contributing to disease initiation and progression. Aneuploidy: Recent studies utilizing single-cell sequencing technologies to dissect the clonal evolution of ALL have revealed that aneuploidy, particularly hyperdiploidy, can occur early in leukemogenesis, contributing to clonal diversity and the progression of ALL.[27] Chromosomal translocations: Recent studies have identified new fusion genes in ALL, such as DUX4 rearrangements and KMT2A mutations in infant ALL, highlighting the heterogeneity of this disease. Research is focused on understanding how these fusion genes disrupt gene expression and signaling pathways, driving leukemic transformation.[28][29] Gene mutations: Gene mutations are a central factor in the development and progression of ALL, with both loss-of-function and gain-of-function mutations contributing to leukemogenesis. Loss-of-function mutations: Recent studies have identified novel tumor suppressor genes involved in ALL, such as TP53, RB1, and CREBBP.[20][30] These mutations disrupt cell cycle regulation, DNA damage repair, and epigenetic control, thereby contributing to uncontrolled cell growth and survival. Gain-of-function mutations: Mutations in signaling pathways, such as JAK/STAT and PI3K/AKT/mTOR, are increasingly recognized as important drivers of ALL. These mutations activate signaling cascades that promote cell proliferation, survival, and drug resistance.[20] Mutations in genes involved in B-cell development: Recent research highlights the role of mutations in genes such as PAX5 and IKZF1 in disrupting normal B-cell differentiation. These genetic alterations are key contributors to the pathogenesis of B-cell precursor ALL.[20][31] Acute Myeloid Leukemia

Gain-of-function mutations: Mutations in signaling pathways, such as JAK/STAT and PI3K/AKT/mTOR, are increasingly recognized as important drivers of ALL. These mutations activate signaling cascades that promote cell proliferation, survival, and drug resistance.[20] Mutations in genes involved in B-cell development: Recent research highlights the role of mutations in genes such as PAX5 and IKZF1 in disrupting normal B-cell differentiation. These genetic alterations are key contributors to the pathogenesis of B-cell precursor ALL.[20][31] Acute Myeloid Leukemia AML arises from myeloid progenitor cells, which are responsible for the production of granulocytes, monocytes, erythrocytes, and platelets. The clonal expansion of myeloid blasts within the bone marrow impairs normal hematopoiesis, resulting in reduced production of mature blood cells. This disruption manifests clinically as anemia, increased susceptibility to infections, and a heightened risk of bleeding. In addition, leukemic blasts may infiltrate extramedullary sites such as the skin, gums, and CNS, contributing to organ-specific complications and extramedullary disease. Please see StatPearls' companion resource, "Acute Myeloid Leukemia," for more information. The pathophysiology of AML is multifaceted and complex, driven by a multitude of genetic and epigenetic alterations. These include chromosomal abnormalities such as translocations, inversions, and deletions, as well as mutations in genes regulating myeloid cell proliferation, differentiation, and survival. These specific genetic alterations are critical in determining the disease's aggressiveness, response to treatment, and prognosis.[32] Broadly, these alterations can be classified into 2 categories based on their functional consequences, as outlined below. Class I mutations: Mutations in genes such as IDH1, IDH2, and DNMT3A have emerged as critical contributors to AML pathogenesis. These mutations alter cellular metabolism, epigenetic regulation, and DNA methylation, thereby contributing to clonal expansion and impaired differentiation.[33]

The pathophysiology of AML is multifaceted and complex, driven by a multitude of genetic and epigenetic alterations. These include chromosomal abnormalities such as translocations, inversions, and deletions, as well as mutations in genes regulating myeloid cell proliferation, differentiation, and survival. These specific genetic alterations are critical in determining the disease's aggressiveness, response to treatment, and prognosis.[32] Broadly, these alterations can be classified into 2 categories based on their functional consequences, as outlined below. Class I mutations: Mutations in genes such as IDH1, IDH2, and DNMT3A have emerged as critical contributors to AML pathogenesis. These mutations alter cellular metabolism, epigenetic regulation, and DNA methylation, thereby contributing to clonal expansion and impaired differentiation.[33] Class II mutations: Recent studies have identified novel mutations in transcription factors such as KMT2A and NUP98, which disrupt normal hematopoietic differentiation and contribute to AML pathogenesis. These mutations alter gene expression patterns and impair myeloid cell maturation, leading to the accumulation of immature blasts.[33][34] Microenvironmental Factors The bone marrow microenvironment is crucial in supporting the survival and proliferation of leukemic cells. Recent research has focused on understanding how interactions between leukemic cells, stromal cells, extracellular matrix components, and inflammatory cytokines contribute to leukemogenesis and drug resistance. These interactions can promote leukemic stem cell self-renewal, suppress immune responses, and protect leukemic cells from chemotherapy-induced cell death.[35]

Laboratory evaluation is crucial in managing acute leukemia by guiding diagnosis, prognosis, and treatment decisions. Optimizing laboratory procedures and adopting a multidisciplinary approach can significantly improve healthcare outcomes. Adhering to standardized protocols for specimen collection, handling, and processing, as recommended by the College of American Pathologists and the American Society of Hematology, ensures consistent and reliable results. This approach minimizes errors and improves diagnostic accuracy. Early and comprehensive testing—including CBC, PBS, BMA/BMB, flow cytometry, cytogenetics, and molecular analysis—facilitates timely diagnosis and the development of personalized treatment plans, leading to improved patient outcomes. Effective communication and collaboration among clinicians, pathologists, and laboratory scientists are essential for optimal patient care. Regular multidisciplinary discussions support the interpretation of complex laboratory findings, promote appropriate test utilization, and ensure the implementation of personalized treatment plans. Integrating molecular testing into the diagnostic process enhances understanding of the genetic landscape of acute leukemia, identifies prognostic markers, refines risk stratification, and informs the selection of targeted therapies, ultimately enabling more effective treatment strategies. Clear and concise reporting of laboratory results using standardized formats enhances communication among healthcare team members. Clinical decision-support tools further assist in interpreting complex data and offer evidence-based recommendations for additional testing and treatment options. Regular monitoring of laboratory performance, coupled with continuing education for healthcare professionals, ensures the delivery of accurate diagnostic information and optimal treatment recommendations. These measures collectively contribute to improved patient outcomes and quality of care.